Tune in to the Journal Club's Fall 2022 installment, The ABCs of ADCs, where panelists discuss antibody drug conjugates for gynecologic cancers including tisotumab vetodin, mirvetuximab soravtansine, as well as strategies in managing side effects and toxicities.